Cipla Licenses HER2 Cancer Drug TQB2102 Across Emerging Markets

Cipla Limited and Sino Biopharmaceutical’s subsidiary Chia Tai Tianqing Pharmaceutical Group (CTTQ) have entered into an exclusive licensing and supply agreement for TQB2102, an investigational HER2-targeted antibody-drug conjugate (ADC).

Under the agreement, Cipla will receive exclusive rights to develop and commercialise TQB2102 in India, South Africa and five other emerging markets. The company will handle local clinical development, regulatory activities and commercialisation in these territories, while CTTQ will continue to manufacture and supply the drug.

TQB2102, also known as rolditamig deuderuxtecan, is being developed for the treatment of HER2-expressing cancers. The drug has shown encouraging clinical potential in patients with HER2-low advanced breast cancer, an area where treatment options remain an important unmet need.

The partnership combines CTTQ’s oncology drug development and manufacturing capabilities with Cipla’s established presence in India, South Africa and other emerging markets. Cipla will use its regulatory, medical, market access and commercial capabilities to support the local development of TQB2102.

The companies said the agreement is aimed at speeding up clinical development and regulatory approvals in the licensed markets. Any commercial launch will depend on receiving the required approvals from local health authorities.

Achin Gupta, Managing Director and Global Chief Executive Officer of Cipla, said the partnership strengthens the company’s oncology portfolio with a promising HER2-targeted ADC and supports its goal of improving access to treatments for patients with significant unmet medical needs.

Eric Tse, CEO of SBP Group, said expanding access to medicines developed by the group is an important part of its global strategy. He added that Cipla’s scale and local expertise make it a suitable partner for bringing TQB2102 to patients in India, South Africa and other emerging markets.

Antibody-drug conjugates are designed to deliver cancer-killing medicines directly to cells carrying specific targets. HER2-targeted ADCs have become an important area of cancer research, particularly as researchers work to develop treatments for patients with different levels of HER2 expression.

TQB2102 is being evaluated across several HER2-expressing cancers, with clinical development continuing to assess its potential across different patient groups.

For Cipla, the agreement adds a late-stage oncology asset to its portfolio and expands its focus on targeted cancer therapies. For SBP Group and CTTQ, the deal provides a pathway to expand the reach of TQB2102 beyond their existing markets.

The companies will now work toward local clinical and regulatory development of TQB2102 across the licensed territories, with the potential to broaden access to the investigational HER2 therapy if it receives the necessary regulatory approvals.